Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Pharmacological Prevention And Treatment Of Acute Pancreatitis: Where Are We Now?

P. Lankisch, M. Lerch
Published 2006 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Acute pancreatitis is a disease of increasing prevalence, unchanged mortality over many decades, and limited treatment strategies. Progress has been made in developing therapies that reduce the rate of endoscopic retrograde cholangiopancreatography (ERCP)-associated pancreatitis and in preventing infected pancreatic necrosis with intravenous carbapenems. Attempts at reducing pancreatic enzyme output or inhibiting the activity of digestive enzyme proteases have not yielded encouraging results – nor have anti-inflammatory strategies for the treatment of acute pancreatitis been found to be effective so far. Future therapeutic options that are presently being developed or under investigation attempt to restore pancreatic secretory function, interfere with inflammatory pathways in a more effective manner, or inhibit digestive enzyme proteases more selectively.
This paper references
Can somatostatin prevent injection pancreatitis after ERCP?
B. Persson (1992)
10.1080/00365520310006540
Intravenous n‐acetylcysteine, ascorbic acid and selenium‐based anti‐oxidant therapy in severe acute pancreatitis
I. T. Virlos (2003)
10.1136/bmj.328.7454.1466
Hospital admission for acute pancreatitis in an English population, 1963-98: database study of incidence and mortality
M. Goldacre (2004)
10.1067/MGE.2002.122614
Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial.
S. Manolakopoulos (2002)
10.1016/S1091-255X(01)80021-4
Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis—a single-center randomized study
I. Nordback (2001)
10.1097/00006676-199710000-00001
ERCP‐Induced Acute Necrotizing Pancreatitis: Is It a More Severe Disease?
A. S. Fung (1997)
10.1007/BF01655075
A controlled trial of synthetic salmon calcitonin in the treatment of severe acute pancreatitis
E. Martínez (2005)
10.1136/gut.48.1.62
Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis
C. Johnson (2001)
Epidurale Blockade zur Analgesie und Behandlung der akuten Pankreatitis
H. Niesel (1991)
10.1016/J.GIE.2005.04.024
Post-ERCP pancreatitis: is allopurinol the Holy Grail?
G. Harewood (2005)
10.1136/gut.45.1.97
A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis
W. Uhl (1999)
10.1136/gut.42.2008.s1
United Kingdom guidelines for the management of acute pancreatitis
G. Glazer (1998)
10.1159/000076541
Procaine Hydrochloride Fails to Relieve Pain in Patients with Acute Pancreatitis
S. Kahl (2004)
10.1053/J.GASTRO.2003.12.050
Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial.
R. Isenmann (2004)
A multicentre controlled clinical trial of high-volume fresh frozen plasma therapy in prognostically severe acute pancreatitis.
T. Leese (1991)
A fi fteen year experience with open drainage for infected pancreatic necro
EL Bradley (1993)
Mortality in acute pancreatitis in Turku University Central Hospital 1971-1995.
Grönroos Jm (1999)
10.1046/j.1440-1746.17.s1.2.x
Guidelines for the management of acute pancreatitis
J. Toouli (2002)
10.1002/BJS.1800610303
A controlled trial of Trasylol in the treatment of acute pancreatitis
J. Trapnell (1974)
10.1016/S0016-5085(98)70030-7
Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis.
C. Bassi (1998)
The infl u - ence of somatostatin on pancreatic irritation after pancreatography : an experimental and clinical study
A Saari (1988)
10.1055/S-0028-1103955
Einfluß von Salm-Calcitonin auf den Verlauf der akuten Pankreatitis
F. Paul (1979)
10.1053/gast.2001.26047
Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography.
J. Deviére (2001)
10.1002/BJS.1800821039
Randomized, double‐blind phase II trial of Lexipafant, a platelet‐activating factor antagonist, in human acute pancreatitis
A. Kingsnorth (1995)
10.1016/S1542-3565(04)00295-2
Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
A. Andriulli (2004)
10.1016/S0016-5107(95)70128-1
A comparison of nonionic versus ionic contrast media: results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group.
G. K. Johnson (1995)
10.1016/S0016-5107(95)70014-5
Use of corticosteroids in the prevention of post-ERCP pancreatitis.
G. R. Weiner (1995)
Infl ammatory mediators and cytokines – new aspects of the pathophysiology and assessment of severity of acute pancreatitis ?
LJ Formela (1993)
10.1097/00006676-198711000-00013
Controlled Trial of Protease Inhibitor Gabexelate Mesilate (FOY) in the Treatment of Acute Pancreatitis
C. Yang (1987)
10.1055/S-2007-1013022
Iopamidol as contrast medium in endoscopic retrograde pancreatography: a prospective randomised comparison with diatrizoate.
H. J. O'Connor (1988)
10.1002/BJS.1800701205
Treatment of acute pancreatitis with fresh frozen plasma
A. Cuschieri (1983)
10.1097/00006676-200211000-00015
What is the risk of alcoholic pancreatitis in heavy drinkers?
P. Lankisch (2002)
10.1053/APNR.2002.29532
Transdermal fentanyl for the management of acute pancreatitis pain.
M. Stevens (2002)
10.1159/000055817
Fatal Outcome in Acute Pancreatitis: Its Occurrence and Early Prediction
T. Blum (2001)
SSAT patient care guidelines : treatment of acute pancreatitis
C Dervenis (1998)
10.3109/00365527109179941
Epsilon-aminocaproic acid in treatment of acute pancreatitis.
Y. Konttinen (1971)
Prophylactic Antibiotics in Treatment of Severe Acute Alcoholic Pancreatitis
R. Delcenserie (1996)
10.1016/0016-5085(93)91102-N
Gabexate mesilate in human acute pancreatitis.
T. Yoshida (1993)
10.1067/MGE.2003.307
Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
S. Sherman (2003)
cagon therapy in acute pancreatitis : report of a double - blind trial
HK Dürr (1977)
10.1016/S0016-5107(85)72018-4
Hyperamylasemia after ERCP with ionic and non-ionic contrast media.
B. Hannigan (1985)
Octreo - tide versus hydrocortisone versus placebo in the prevention of post - ERCP pancreatitis : a multicenter randomized controlled trial
S Manolakopoulos (2002)
The German Pancreatitis Study Group: A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis
W Uhl (1999)
10.1007/BF02064970
Effectiveness of gabexate mesilate in acute pancreatitis
A. Messori (2005)
10.1055/S-2001-16520
A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis.
A. Budzyńska (2001)
10.1016/0016-5085(86)90579-2
Bacterial contamination of pancreatic necrosis. A prospective clinical study.
H. Beger (1986)
10.1086/375603
Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy.
J. D. De Waele (2003)
10.1046/j.1365-2036.2001.01015.x
Octreotide 24‐h prophylaxis in patients at high risk for post‐ERCP pancreatitis: results of a multicenter, randomized, controlled trial
P. Testoni (2001)
10.1055/S-2007-1013018
A randomised, prospective study comparing two contrast media in ERCP.
W. Cunliffe (1987)
10.3109/00365528509088825
Indomethacin treatment of acute pancreatitis. A controlled double-blind trial.
N. Ebbehøj (1985)
10.1016/S1072-7515(02)01494-1
Prophylactic antibiotics alter the bacteriology of infected necrosis in severe acute pancreatitis.
T. Howard (2002)
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography.
J. Schneider (1997)
10.1159/000076540
No More Intravenous Procaine for Pancreatitis Pain?
M. Lerch (2004)
10.1007/BF02798921
Fatal pancreatitis, a consequence of excessive leukocyte stimulation?
H. Rinderknecht (1988)
10.1046/J.1365-2168.1997.00512.X
Prospective placebo‐controlled randomized trial of lexipafant in predicted severe acute pancreatitis
C. Mckay (1997)
10.1053/GAST.2000.17934
What is the risk of biliary pancreatitis in patients with gallstones?
A. Lowenfels (2000)
10.7326/0003-4819-83-6-831
The Use of Ampicillin in Acute Pancreatitis
R. Craig (1975)
Inflammatory mediators and cytokines--new aspects of the pathophysiology and assessment of severity of acute pancreatitis?
V. Gross (1993)
10.1016/S0016-5107(94)70204-7
Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent.
S. Sherman (1994)
10.1097/00006676-200311000-00018
Prophylaxis with Meropenem of Septic Complications in Acute Pancreatitis: A Randomized, Controlled Trial Versus Imipenem
G. Manes (2003)
10.1016/S0016-5107(05)01574-9
Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis.
P. Katsinelos (2005)
10.3109/00365528009181808
Experimental pancreatitis in the rat. The role of phospholipase A in sodium taurocholate-induced acute haemorrhagic pancreatitis.
H. Aho (1980)
10.1136/gut.19.3.175
Glucagon therapy in acute pancreatitis. Report of a double-blind trial.
H. Dürr (1978)
10.1097/00006676-200101000-00005
Prophylactic Antibiotic Administration Reduces Sepsis and Mortality in Acute Necrotizing Pancreatitis: A Meta-Analysis
V. Sharma (2001)
10.1097/00000441-195211000-00004
The use of fractional epidural block in the management of acute pancreatitis.
Berk Je (1952)
10.1016/S0140-6736(95)92280-6
Early antibiotic treatment in acute necrotising pancreatitis
V. Sainio (1995)
[Controlled therapeutic trial of aprotinin and glucagon in acute pancreatitis (author's transl)].
A. Gauthier (1978)
10.1016/S0140-6736(78)92965-3
DEATH FROM ACUTE PANCREATITIS
N. Back (1978)
10.3109/00365527909181935
Ampicillin concentrations in pancreatic fluid bile obtained at endoscopic retrograde cholangiopancreatography (ERCP).
E. Roberts (1979)
Evaluation of atropine in acute pancreatitis.
J. Cameron (1979)
10.1128/AAC.38.4.830
Behavior of antibiotics during human necrotizing pancreatitis.
C. Bassi (1994)
10.1159/000201021
Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography.
J. A. Sand (1993)
Einfl uss von Salm - Calcitonin auf den Verlauf der akuten Pankreatitis . Ergebnisse einer prospektiven Doppelblindstudie
E Martinez (1979)
10.1007/s00108-003-1067-5
Therapie der akuten Pankreatitis
J. Mössner (2003)
10.1016/S0002-9270(03)00704-4
Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
E. Masci (2003)
10.1007/BF02785915
A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis
C. Mckay (1997)
10.1023/B:DDAS.0000020511.98230.20
Role of Osmolality of Contrast Media in the Development of Post-ERCP Pancreatitis: A Metanalysis
S. George (2004)
10.1016/S0016-5107(99)70387-1
Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial.
R. Poon (1999)
10.1016/0022-4804(75)90016-5
Evaluation of prophylactic antibiotics in acute pancreatitis.
R. Howes (1975)
10.1056/NEJM199609263351302
Gabexate mesilate for the prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography.
G. Cavallini (1996)
10.1001/ARCHSURG.1993.01420170122019
A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992.
E. L. Bradley (1993)
10.1016/S0016-5085(83)80011-0
Effects of prostaglandin and indomethacin on diet-induced acute pancreatitis in mice.
E. Coelle (1983)
A randomized double-blind trial of glucagon in treatment of first attack of severe acute pancreatitis without associated biliary disease.
O. Kronborg (1980)
10.1136/gut.21.4.334
Morbidity of acute pancreatitis: the effect of aprotinin and glucagon.
(1980)
10.5555/uri:pii:0016508578902822
Failure of glucagon in the treatment of alcoholic pancreatitis.
A. Olazábal (1978)
10.1097/00000658-197606000-00008
A Prospective Study to Determine the Efficacy of Antibiotics in Acute Pancreatitis
W. Finch (1976)
A mul - ticentre controlled clinical trial of high - volume fresh frozen plasma therapy in prognos - tically severe acute pancreatitis
H Rinderknecht (1991)
10.1055/S-2008-1047621
[Antibiotic use in necrotizing pancreatitis. Results of a controlled study].
M. Schwarz (1997)
10.1046/j.1365-2036.1998.00295.x
Meta‐analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis
Andriulli (1998)
10.1002/BJS.1800741012
Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis
T. Leese (1987)
10.1016/0016-5085(87)90261-7
Early diagnosis of pancreatic infection by computed tomography-guided aspiration.
S. Gerzof (1987)
Mortality in acute pancreatitis in Turku University Central Hospital 1971-1995.
J. Grönroos (1999)
tically severe acute pancreatitis
H Rinderknecht (1991)
Allopurinol for preventing postERCP pancreatitis
S Sherman (2005)
trolled trial of protease inhibitor gabexelate mesilate ( FOY ) in the treatment of acute pancreatitis
H Goebell (1987)
10.1016/S0016-5107(05)01572-5
Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis.
P. Mosler (2005)
10.1111/j.1440-1746.2003.03297.x
Can somatostatin prevent post‐ERCP pancreatitis? Results of a randomized controlled trial
D. Arvanitidis (2004)
10.1016/0005-2760(76)90284-8
Effects of local anaesthetics on phospholipases.
H. Kunze (1976)
10.1007/S005340200051
Evidence-based clinical practice guidelines for acute pancreatitis: proposals.
T. Mayumi (2002)
Experimental acute pancreatitis induced by platelet activating factor in rabbits.
G. Emanuelli (1989)
Observations during treatment of acute pancreatitis with insulin and glucose infusion.
D. Hallberg (1974)
10.1016/S0016-5107(04)00159-2
Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis.
T. Rabenstein (2004)
Role of intravenously infused insulin in treatment of acute pancreatitis. A double-blind study.
J. Svensson (1975)
10.3109/00365527909181420
A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis.
H. Goebell (1979)
Antibiotika bei nekrotisierender Pankreatitis. Ergebnisse einer kontrollierten Studie
M Schwarz (1997)
10.1002/BJS.1800811224
Amelioration of experimental acute pancreatitis with a potent platelet‐activating factor antagonist
L. Formela (1994)
10.1016/S0016-5107(02)70178-8
Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study.
F. Prat (2002)
10.1159/000180981
Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy.
J. Bordas (1988)
10.1111/j.1572-0241.1998.061_c.x
Pretreatment With Methylprednisolone to Prevent Ercp-Induced Pancreatitis: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
J. Dumot (1998)
Anwendung der Epiduralanästhesie bei Patienten mit akuter Pankreatitis – Prospektive Untersuchung an 121 Patienten
A Bernhardt (2002)
A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis.
I. Gjørup (1992)
10.1016/S1091-255X(98)80048-6
Role of antibiotics in acute pancreatitis: A meta-analysis
R. Golub (1998)
10.1053/GAST.1996.V110.PM8536862
Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis.
K. Mithoefer (1996)
10.1016/0016-5085(93)90288-N
Gabexate mesilate in human acute pancreatitis
M. Buechler (1993)
10.1136/rapm-00115550-199520060-00011
Continuous Celiac Plexus Block in Acute Pancreatitis
J. Rykowski (1995)
10.1080/003655200453692
Buprenorphine or procaine for pain relief in acute pancreatitis. A prospective randomized study.
R. Jakobs (2000)
THE USE OF FRACTIONAL EPIDURAL BLOCK IN THE MANAGEMENT OF ACUTE PANCREATITIS
J. Berk (1952)
10.1067/MGE.2003.29
Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial.
M. Moretó (2003)
Infl ammatory mediators in acute pancreati
CD Johnson (1995)
10.1111/j.1572-0241.2001.04092.x
A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis
J. Dumot (2001)
10.1016/0016-5085(92)91450-I
Human pancreatic tissue concentration of bactericidal antibiotics.
M. Buechler (1992)
EHL: A controlled trial of Trasylol in the treatment of acute pancreatitis
JE Trapnell (1974)
10.3109/00365519709084587
Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro.
A. Mäkelä (1997)
10.1385/IJGC:28:2:091
Does mortality occur early or late in acute pancreatitis?
M. Mutinga (2000)
10.1056/NEJM199609263351302
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
G. Cavallini (1996)
10.1016/S0016-5107(00)14046-5
3346 Evaluation of recombinant human plateletactivating factor acetylhydrolase (rpaf-ah) for reducing the incidence and severity of post-ercp acute pancreatitis (ap).
S. Sherman (2000)
10.1136/gut.40.1.80
Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis.
H. Messmann (1997)
10.1136/gut.45.2.311
The role of infection in acute pancreatitis
S. Schmid (1999)
10.1111/j.1572-0241.2003.07698.x
Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis
E. Masci (2003)
10.1016/S0016-5107(95)90002-0
The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy.
R. Arcidiacono (1994)
CT-guided aspiration of suspected pancreatic infection: bacteriology and clinical outcome.
P. Banks (1995)
10.1067/MGE.2002.122616
Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP?
T. Rabenstein (2002)
10.1007/BF01296438
Effect of somatostatin analog octreotide on human sphincter of Oddi
K. Binmoeller (2005)
10.1097/00000658-200003000-00008
Pathophysiologic role of oxygen free radicals in acute pancreatitis: initiating event or mediator of tissue damage?
B. Rau (2000)
A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis.
J. Sternlieb (1992)
10.1001/ARCHSURG.136.5.592
Pancreatic infection in severe pancreatitis: the role of fungus and multiresistant organisms.
B. Gloor (2001)
10.1159/000055813
Acute Pancreatitis: Threat of Fungal Infection
B. Gloor (2001)
10.1016/S0016-5107(04)00353-0
Prevention of post-ERCP pancreatitis: a comprehensive review.
M. Freeman (2004)
Infl uence of gastrointestinal hormones on the course of acute experimental pancreatitis
PG Lankisch (1982)
10.1097/00006676-200408000-00018
Natural beta-carotene for the prevention of post-ERCP pancreatitis.
A. Lavy (2004)
10.1016/S1091-255X(01)80059-7
Post-ERCP pancreatitis: Reduction by routine antibiotics
S. Räty (2001)
10.1016/0016-5085(90)90633-C
Pancreatic exocrine secretion in acute experimental pancreatitis.
C. Niederau (1990)
10.1080/00365521.1975.12097000
Role of intravenously infused insulin in treatment of acute pancreatitis. A double-blind study.
Svensson Jo (1975)
10.1385/IJGC:25:2:103
Mortality from acute pancreatitis
A. Lowham (1999)
10.1002/BJS.1800650514
A single‐centre double‐blind trial of Trasylol therapy in primary acute pancreatitis
C. Imrie (1978)
10.1097/00006676-199205000-00023
ERCP and endoscopic sphincterotomy-induced pancreatitis.
S. Sherman (1994)
10.1007/s00063-004-1104-8
Untersuchung zur antioxidativen Therapie mit Natriumselenit bei akuter Pankreatitis
D. Lindner (2004)
Secondary pancreatic infections: are they distinct clinical entities?
I. Fedorak (1992)
10.1136/gut.33.9.1268
Role of platelet activating factor in pathogenesis of acute pancreatitis in rats.
S. Konturek (1992)
10.1097/01.MCG.0000196407.53228.AD
The role of antibiotic prophylaxis in the treatment of acute pancreatitis.
M. Ratschko (1999)
10.1016/S0016-5107(02)70431-8
Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
A. Andriulli (2002)
Krumperman LRW: The use of fractional epidural block in the management of acute pancreatitis
JE Berk (1952)
Multicenter double-blind study of gabexate mesilate (Foy), given intravenously in low dose in acute pancreatitis (abstr)
H Goebell (1988)
DV: United Kingdom guidelines for the management of acute pancreatitis
G Glazer (1998)
10.1213/00000539-198805000-00013
Interpleural catheter analgesia for pancreatic pain.
Z. Durrani (1988)
10.1016/S0016-5107(04)02647-1
High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial.
P. Katsinelos (2005)
10.1016/S0016-5107(00)70377-4
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
A. Andriulli (2000)
Treatment of acute pancreatitis with somatostatin: results of the multicenter double-blind trial (APTS-study) (abstract)
KH Usadel (1985)
Akute Pankreatitis – eine ‘ Free Radical Disease ’
IT Virlos (1991)
Étude contrôlée multicentrique de l’aprotinine et du glucagon dans le traitement des pancréatites aiguës
A Gauthier (1978)
10.1159/000198888
Influence of secretin on the course of acute experimental pancreatitis in rats.
P. Lankisch (1983)
10.1007/BF02924640
Influence of a platelet-activating factor antagonist on severe pancreatitis in two experimental models
U. Leonhardt (1992)
10.1046/J.0007-1323.2001.01842.X
Prospective randomized double‐blind placebo‐controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography‐induced pancreatitis
S. Sudhindran (2001)
10.1055/S-2000-7447
Therapie der akuten Pankreatitis : Gemeinsame Leitlinien
M. Ruenzi (2000)
10.1046/j.1365-2036.1998.00414.x
Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography
Tulassay (1998)
10.1046/J.1365-2168.1999.01246.X
High early mortality rate from acute pancreatitis in Scotland, 1984–1995
C. Mckay (1999)
10.1002/BJS.1800820105
Inflammatory mediators in acute pancreatitis
L. Formela (1995)
10.1155/1995/89612
Pancreatic Enzyme Supplementation in Acute Pancreatitis
R. Patankar (1995)
10.1159/000071181
IAP Guidelines for the Surgical Management of Acute Pancreatitis
W. Uhl (2003)
10.1007/BF02925968
Diagnosis, objective assessment of severity, and management of acute pancreatitis
C. Dervenis (1999)
10.1053/J.GASTRO.2004.02.027
Prophylactic antibiotic use in severe acute pancreatitis: hemlock, help, or hype?
A. Brown (2004)
10.3109/00365527809181774
Indomethacin treatment of acute experimental pancreatitis in the rat.
P. Lankisch (1978)
10.1007/BF02784951
CT-guided aspiration of suspected pancreatic infection
P. Banks (1995)
Influence of gastrointestinal hormones on the course of acute experimental pancreatitis.
A. Evander (1982)
A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem.
P. Pederzoli (1993)
10.1016/S0016-5107(03)02540-9
The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis.
Jeremy J. Schwartz (2004)
10.1007/BF02788371
Risk of death from acute pancreatitis
G. Talamini (1996)
10.1111/j.1572-0241.1999.999_u.x
Use of corticosteroids in the prevention of post-ERCP pancreatitis: results of a controlled prospective study
G. D. Palma (1999)
10.1053/J.GASTRO.2003.12.035
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Olusola Oiofinlade (2004)
10.1002/(SICI)1096-9896(200002)190:2<117::AID-PATH494>3.0.CO;2-K
Inflammatory mediators in acute pancreatitis
M. Bhatia (2000)



This paper is referenced by
10.2217/pgs-2016-0176
Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.
S. Allegra (2017)
10.1097/MPA.0000000000000656
Up-regulation of Tight-Junction Proteins by p38 Mitogen-Activated Protein Kinase/p53 Inhibition Leads to a Reduction of Injury to the Intestinal Mucosal Barrier in Severe Acute Pancreatitis
J. Ouyang (2016)
10.1007/s00063-007-1093-5
Akute Pankreatitis: Worauf es wirklich ankommt in der Diagnostik und der Therapie*
H. Lübbers (2007)
10.1111/j.1440-1746.2011.07011.x
Differential roles of inflammatory cells in pancreatitis
J. Mayerle (2012)
10.3892/mmr.2014.1996
Berberine ameliorates severe acute pancreatitis‑induced intestinal barrier dysfunction via a myosin light chain phosphorylation‑dependent pathway.
Hong-yin Liang (2014)
10.3748/WJG.14.2968
Pharmacological approach to acute pancreatitis.
U. Bang (2008)
10.1097/MPG.0000000000000360
Update to the Management of Pediatric Acute Pancreatitis: Highlighting Areas in Need of Research
Maisam A Abu-El-Haija (2014)
10.5152/UCD.2015.3170
Effects of everolimus on a rat model of cerulein-induced experimental acute pancreatitis.
A. Özkardeş (2015)
10.3748/WJG.14.4546
Delayed ethyl pyruvate therapy attenuates experimental severe acute pancreatitis via reduced serum high mobility group box 1 levels in rats.
Z. Yang (2008)
10.18632/oncotarget.15515
Granulocyte colony-stimulating factor enhances the therapeutic efficacy of bone marrow mesenchymal stem cell transplantation in rats with experimental acute pancreatitis
B. Qu (2017)
10.1016/j.arcmed.2019.02.003
High Serum Levels of High-Mobility Group Box 1 (HMGB1) and Low Levels of Heat Shock Protein 70 (Hsp70) are Associated with Poor Prognosis in Patients with Acute Pancreatitis.
L. Arriaga-Pizano (2018)
10.1097/MPG.0000000000002186
Updates in Pediatric Pancreatology: Proceedings of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Frontiers in Pediatric Pancreatology Symposium.
A. Grover (2019)
10.1111/1751-2980.12148
Time course of intestinal barrier function injury in a sodium taurocholate‐induced severe acute pancreatitis in rat model
H. Liang (2014)
10.1016/j.jcyt.2012.11.007
Effect of umbilical cord mesenchymal stem cells on treatment of severe acute pancreatitis in rats.
B. Yang (2013)
10.3410/M1-59
Advances in managing acute pancreatitis
M. DiMagno (2009)
10.3748/WJG.14.6551
Study on protecting effects of baicalin and octreotide on hepatic injury in rats with severe acute pancreatitis.
X. Zhang (2008)
10.1016/j.peptides.2012.12.018
High-dose versus low-dose octreotide in the treatment of acute pancreatitis: A randomized controlled trial
R. Wang (2013)
10.1097/MPA.0b013e31823cd3ef
Therapeutic Treatment With Ethyl Pyruvate Attenuates the Severity of Liver Injury in Rats With Severe Acute Pancreatitis
Z. Luan (2012)
10.1631/jzus.B1000044
Clodronate-containing liposomes attenuate lung injury in rats with severe acute pancreatitis
S. Dang (2010)
10.1016/S1726-4901(09)70023-1
Somatostatin for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a never-ending story?
Chun-Chia Chen (2009)
10.1159/000092477
Advances in GI Pharmacology and Therapeutics
C. Scarpignato (2006)
10.4172/2155-9929.1000257
Pathophysiology of Oxidative Stress and Antioxidant Therapy in Acute Pancreatitis
S. Meher (2015)
10.1016/S1499-3872(11)60092-1
Protective effect of clodronate-containing liposomes on intestinal mucosal injury in rats with severe acute pancreatitis.
J. Zhang (2011)
10.1097/MPA.0b013e3181bab5c5
Role of High-Mobility Group Box 1 Protein in the Pathogenesis of Intestinal Barrier Injury in Rats With Severe Acute Pancreatitis
Z. Luan (2010)
10.3748/wjg.v20.i41.15200
Immune-modulating therapy in acute pancreatitis: fact or fiction.
K. Akinosoglou (2014)
10.1159/000108956
Nitric Oxide Pathways and Evidence-Based Perturbations in Acute Pancreatitis
M. DiMagno (2007)
10.1136/gut.2009.186692
A novel role for leucocytes in determining the severity of acute pancreatitis
J. Mayerle (2009)
Diosmetin ameliorates the severity of cerulein-induced acute pancreatitis in mice by inhibiting the activation of the nuclear factor-κB.
Ge Yu (2014)
10.1053/j.gastro.2010.11.047
Human bone marrow-derived clonal mesenchymal stem cells inhibit inflammation and reduce acute pancreatitis in rats.
Kyung Hee Jung (2011)
10.1016/j.cgh.2008.11.020
Alcohol use and cigarette smoking as risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis.
Anthony T Debenedet (2009)
10.1016/j.ejphar.2010.06.020
Effect of pentoxifylline and/or alpha lipoic acid on experimentally induced acute pancreatitis.
Amany A. Abdin (2010)
Efficacy of Diclofenac Sodium Versus Somatostatin for the Prevention of Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography
A. Elbaih (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar